4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting

24 سبتمبر 2021 06:03:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights

12 أغسطس 2021 15:04:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement

24 يونيو 2021 06:01:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief Business Officer

07 يونيو 2021 06:00:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

03 يونيو 2021 06:00:01 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights

13 مايو 2021 15:03:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME

12 مايو 2021 16:30:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform

04 مايو 2021 15:02:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference

30 أبريل 2021 06:05:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies

27 أبريل 2021 15:31:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights

25 مارس 2021 15:02:00 بحسب Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease

09 مارس 2021 07:03:00 بحسب Nasdaq GlobeNewswire